Increasing Growth Rate of Global Polycystic Kidney Disease (PKD) Results in New Drug Discoveries, Supporting Market’s Development

Published Date : May 16, 2016

ALBANY, New York, May 16, 2016 - has added a new report, ‘Polycystic Kidney Disease (PKD)-Market Insights, Epidemiology And Market Forecast-2020,’ to its offering. This study on the market for polycystic kidney disease is an extensive review of the overall market. It helps in the detailed understanding of the market by elaborating the major factors propelling as well as restraining the growth of the market. In addition, the unmet needs, the major trends, and the chief opportunities in the market have also been elaborated upon in this study. The study also aids in the development and design of in-licensing and out-licensing strategies by presenting a review on the pipeline products as well as technologies. The companies with the most promising pipeline have also been presented in this research report.

The introduction section of the report starts by providing the overview of polycystic kidney disease (PKD). PKD is an inherited disorder affecting one in thousand adults as well as children globally. In this disease, clusters of cysts form inside the kidneys. These cysts are non-cancerous round sacs comprising a water-like fluid and vary in size. Although in this disease, kidneys are the worst affected organs, the disease may also result in cysts in the liver and other organs. This may lead to a number of serious complications. A major and common complication associated with this disease is high blood pressure. In addition, the failure of the kidneys is yet another common problem among people having PKD.

For Sample Copy, click here:

Moving further, the report throws light on the key symptoms, diagnosis, path physiology, disease management, etiology, and present treatment options for PKD. An overview of the major marketed drugs in the market forms the next part of the report. This section entails the drug description, mechanism of action, patent information, pharmacokinetics properties, and treatment of disease.

In the following section of the report, the patent or exclusivity expiry assessment within the U.S. has been presented. An evaluation on the forecasted and historical sales of marketed molecules in the polycystic kidney disease market have also been covered under this section of the report. In addition, the forecast on the epidemiology of polycystic kidney disease has also been presented from 2016 to 2020.

In the next chapter of the report, the market has been segmented on the basis of geography. Under this section, the state of the market has been highlighted in the seven key markets i.e. the U.S., Japan, EU5 nations such as Germany, France, Spain, Italy, and the UK, and Rest of the World (RoW) in 2011 to 2015. In addition, the state of this market in the above mentioned nations in the forecast horizon 2016 to 2020 has also been assessed under this section of the report.

To order report Call Toll Free: 866-997-4948 or send an email on